Home Health WHO approves two new treatments in special cases

WHO approves two new treatments in special cases

WHO approves two new treatments in special cases

The World Health Organization (WHO) has approved two new Covid-19 therapies. In their statement, published today in the British medical journal BMJ, WHO experts recommended the use of the arthritis drug baricitinib and the synthetic antibody-based drug sotrovimab under certain circumstances. Overall, the WHO now recommends five CoV therapies. Sotrovimab is recommended for patients with a mild course of the disease but who have a high risk of hospitalization. These include, for example, the elderly, people with immunodeficiency or chronic diseases such as diabetes. The benefit of sotrovimab for patients who do not belong to risk groups is considered to be small. In addition, according to the WHO experts, the effectiveness of the drug against the highly contagious omicron variant is “still uncertain”. Baricitinib, on the other hand, is recommended for “patients with severe or critical Covid”. The drug, originally developed to fight arthritis, was to be administered “in combination with corticosteroids”. This “improves survival rates and reduces the need for mechanical ventilation” in CoV patients. So far, only three other treatments for Covid-19 disease are recommended by the WHO. Since September 2020, this has included the treatment of seriously ill patients with corticosteroids. Corticosteroids fight inflammation that usually accompanies severe CoV cases. They are inexpensive and widely available. In July, the WHO also endorsed the use of the arthritis drugs tocilizumab and sarilumab.

#approves #treatments #special #cases


Please enter your comment!
Please enter your name here